(Isstories Editorial):- New York City, New York Jul 4, 2023 (Issuewire.com) – Leading CRO company Creative Biolabs has developed a state-of-the-art one-stop platform to address the persistent worldwide danger posed by SARS-CoV-2. The platform facilitates the creation of effective countermeasures ranging from SARS-CoV-2 in vitro diagnosis to vaccine development and drug discovery.
As the world continues to grapple with the challenges posed by SARS-CoV-2, Creative Biolabs has risen to the occasion by delivering exceptional services tailored to address critical aspects of the pandemic response.
One of Creative Biolabs’ main offerings is vaccine development for SARS-CoV-2. Leveraging its advanced technology platform, Creative Biolabs provides comprehensive support throughout the vaccine development process. Its team of experts assists clients in designing, constructing, and optimizing diverse vaccines, paving the way for safe and efficacious immunization strategies.
More on Isstories:
- Brandon Tillemans, Recognized by BestAgents.us as a 2024 Top Agent
- Nikki Froehlich, Recognized by BestAgents.us as a 2024 Top Agent
- Debra Savan, Recognized by BestAgents.us as a 2024 Top Agent
- Antoinette Farina, Recognized by BestAgents.us as a 2024 Top Agent
- Kelli Sager, Recognized by BestAgents.us as a 2024 Top Agent
Currently, Creative Biolabs supports different types of vaccines, including but not limited to:
* In Silico SARS-CoV-2 Vaccine
* SARS-CoV-2 DNA Vaccine
* Recombinant Subunit Vaccine for SARS-CoV-2
Additionally, Creative Biolabs is actively engaged in the search for antiviral drugs. With a deep understanding of viral proteases and their crucial role in viral replication, Creative Biolabs offers customized services to identify and optimize potent protease inhibitors for SARS-CoV-2, aiming to aid in finding promising therapeutics to combat the virus. For instance, Indinavir, Nelfinavir, and Saquinavir are three protease inhibitors that have proven their ability to bind to coronavirus protease.
Moreover, protease assays to assess SARS-CoV-2 protease inhibitors are available from Creative Biolabs, including FRET-based assays, counter-screening assays, spike-pseudovirus-based neutralization assays, SARS-CoV-2-CPE assays, etc.
“Our team is dedicated to leveraging our expertise and resources to offer practical solutions for drug discovery,” stated the chief scientist of Creative Biolabs. “It is also worth mentioning our in vitro diagnosis (IVD) of the novel coronavirus.”
In line with its commitment to advancing diagnostics, Creative Biolabs provides SARS-CoV-2 IVD antibody development services. By harnessing its expertise in immunoassay development, Creative Biolabs offers tailored solutions for the accurate detection of SARS-CoV-2-specific antibodies, including antigen production, antibody development, and the design and development of immunoassays.
Based on an advanced one-stop platform, Creative Biolabs designs highly sensitive and specific assays, such as turbidimetric assays, chemiluminescent assays, and ELISA, which facilitate early detection, surveillance, and control of the spread of the virus.
For more information about comprehensive services in the fight against SARS-CoV-2, please visit https://www.creative-biolabs.com.
About Creative Biolabs
With its diverse portfolio of services, Creative Biolabs is well-positioned to support the global scientific community in its fight against SARS-CoV-2. By combining innovation, expertise, and state-of-the-art facilities, Creative Biolabs specializes in providing advanced solutions for the research and development of anti-SARS-CoV-2 vaccines and drugs.
Candy Swift
